A61K38/204

METHODS FOR PREVENTING AND TREATING CHRONIC PAIN

The present invention relates to a method of preventing or treating chronic pain comprising administering to a subject, in an amount/number effective to elicit, sustain or potentiate an inflammatory process, a pro-inflammatory compound, myeloid leukocyte cells or a substance that increases the number or activity of myeloid leukocyte cells.

COMPOSITIONS FOR BIOLOGICAL SYSTEMS AND METHODS FOR PREPARING AND USING THE SAME
20180264044 · 2018-09-20 ·

A composition for influencing biological growth including live cells, a fluid comprising dextrose, a protectant, and a first cytokine having a first concentration within the composition as described within the present disclosure.

KAPPA MYELOMA ANTIGEN CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF

The present invention provides compositions and methods for treating KMA-expressing malignancies including chimeric antigen receptors (CARs) and T cells containing CARs (CAR T-cells). The invention also provides methods and compositions comprising CAR T-cells co-expressing other anti-tumoral agents including cytokines and antibodies.

TREATMENT OF CANCER USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND IL-6
20180214547 · 2018-08-02 ·

This disclosure provides a method for treating a subject afflicted with a cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an anti-cancer agent which is an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and, (b) IL-6.

TREATMENT OF CANCER USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND IL-6
20180214547 · 2018-08-02 ·

This disclosure provides a method for treating a subject afflicted with a cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an anti-cancer agent which is an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and, (b) IL-6.

MODIFIED VACCINIA VIRUS STRAINS FOR USE IN DIAGNOSTIC AND THERAPEUTIC METHODS

Modified viruses and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided. The viruses can be used in methods of treatment of diseases, such as proliferative and inflammatory disorders, including cancer, and as anti-tumor and/or antiangiogenic agents. The viruses also can be used in diagnostic methods.

Methods and compositions using AMPK activators for pharmacological prevention of chronic pain

Methods and compositions using a combination of adenosine monophosphate protein kinase (AMPK) activators for treating pain such as post-surgical pain or development of chronic pain. The two or more AMPK activators work synergistically and may be administered in individually sub-efficacious doses. The AMPK activators may have different mechanisms of AMPK activation. The AMPK activators may be administered systemically and/or topically in, for example, as a gel, ointment, cream, lotion, suspension, liquid, or transdermal patch.

COMPOSITION AND METHOD FOR INDUCING ANTI-INFLAMMATORY RESPONSE
20180185448 · 2018-07-05 ·

The present invention relates generally to metabolic detoxification, and more particularly to a composition and method for inducing an anti-inflammatory response in a cell, as well as treating disease in a subject.

TARGETED GENE DELIVERY FOR DENDRITIC CELL VACCINATION

Methods and compositions are provided for delivery of a polynucleotide encoding a gene of interest, typically an antigen, to a dendritic cell (DC). The virus envelope comprises a DC-SIGN specific targeting molecule. The methods and related compositions can be used to treat patients suffering from a wide range of conditions, including infection, such as HIV/AIDS, and various types of cancers.

Treatment of right ventricular dysfunction due to pressure overload

A method is disclosed for inducing right ventricular (RV) adaptive remodeling in a patient suffering from pulmonary hypertension (PH) due to pressure overload comprising administering a therapeutically effective amount of a carditrophin-1 polypeptide, recombinant protein or a polynucleotide encoding CT-1 polypeptide or full-length protein.